Hiệu quả của thuốc ziv-aflibercept tiêm nội nhãn trên bệnh nhân bị phù hoàng điểm do tắc mạch máu võng mạc tại Bệnh viện Giảng dạy Korle-Bu, Ghana: một loạt ca hồi cứu

Laouri M, Chen E, Looman M, Gallagher M (2011) The burden of disease of retinal vein occlusion: review of the literature. Eye (London, England) 25(8):981–988

Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P et al (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117(2):313-319.e1

Deramo VA, Cox TA, Syed AB, Lee PP, Fekrat S (2003) Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol (Chicago, Ill: 1960) 121(9):1297–302

Awdeh RM, Elsing SH, Deramo VA, Stinnett S, Lee PP, Fekrat S (2010) Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Br J Ophthalmol 94(3):319–323

Noma H, Mimura T, Yasuda K, Shimura M (2014) Role of soluble vascular endothelial growth factor receptors-1 and -2, their ligands, and other factors in branch retinal vein occlusion with macular edema. Invest Ophthalmol Vis Sci 55(6):3878–3885

Noma H, Mimura T, Yasuda K, Shimura M (2015) Role of soluble vascular endothelial growth factor receptor signaling and other factors or cytokines in central retinal vein occlusion with macular edema. Invest Ophthalmol Vis Sci 56(2):1122–1128

Varma R, Bressler NM, Suñer I, Lee P, Dolan CM, Ward J et al (2012) Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology 119(10):2108–2118

Lashay A, Riazi-Esfahani H, Mirghorbani M, Yaseri M (2019) Intravitreal medications for retinal vein occlusion: systematic review and meta-analysis. J Ophthalmic Vis Res 14(3):336–366

Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N et al (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118(10):2041–2049

Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A (2012) Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 119(12):2587–2591

Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ et al (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 121(7):1414-1420.e1

Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U et al (2014) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 158(5):1032–1038

Rajagopal R, Shah GK, Blinder KJ, Altaweel M, Eliott D, Wee R et al (2015) Bevacizumab versus ranibizumab in the treatment of macular edema due to retinal vein occlusion: 6-month results of the CRAVE Study 2015 [updated Sep

cited 46 8]. 2015/10/03:[844-50]

Chhablani J (2015) Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion. Indian J Ophthalmol 63(5):469–470

Paulose R, Chhablani J, Dedhia CJ, Stewart MW, Mansour AM (2016) Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion. Clin Ophthalmol (Auckland, NZ) 10:1853–1858

Chan EW, Eldeeb M, Dedhia CJ, Mansour A, Chhablani J (2018) One-year treatment outcomes of ziv-aflibercept for treatment-naive macular oedema in branch retinal vein occlusion. Acta Ophthalmol 96(2):e256–e257. https://doi.org/10.1111/aos.13432

Eldeeb M, Chan EW, Dedhia CJ, Mansour A, Chhablani J (2017) One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion. Am J Ophthalmol Case Rep 8:58–61

Singh SR, Stewart MW, Chattannavar G, Ashraf M, Souka A, ElDardeery M et al (2019) Safety of 5914 intravitreal ziv-aflibercept injections. Br J Ophthalmol 103(6):805–810. https://doi.org/10.1136/bjophthalmol-2018-312453

Braimah IZ, Kenu E, Amissah-Arthur KN, Akafo S, Kwarteng KO, Amoaku WM (2019) Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: a randomised double-blind intervention study. PLoS ONE 14(10):e0223944

Singh SR, Chattannavar G, Ayachit A, Pimentel MC, Alfaro A, Tiwari S et al (2020) Intravitreal ziv-aflibercept: safety analysis in eyes receiving more than ten intravitreal injections. Semin Ophthalmol 35(1):2–6

Spooner K, Fraser-Bell S, Hong T, Chang AA (2019) Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors. BMJ open Ophthalmol 4(1):e000249

Maggio E, Mete M, Maraone G, Attanasio M, Guerriero M, Pertile G (2020) Intravitreal injections for macular edema secondary to retinal vein occlusion: long-term functional and anatomic outcomes. J Ophthalmol 2020:7817542

Wang JK, Su PY, Hsu YR, Chen YJ, Chen FT, Tseng YY (2016) Comparison of the efficacy of intravitreal aflibercept and bevacizumab for macular edema secondary to branch retinal vein occlusion. J Ophthalmol 2016:8421940

Mansour AM, Al-Ghadban SI, Yunis MH, El-Sabban ME (2015) Ziv-aflibercept in macular disease. Br J Ophthalmol 99(8):1055–1059

Chhablani J, Dedhia CJ, Peguda HK, Stewart M (2017) Short-term safety of 2 mg intravitreal ziv-aflibercept. Retina (Philadelphia, Pa) 37(10):1859–1865

Tsukada K, Tsujikawa A, Murakami T, Ogino K, Yoshimura N (2011) Lamellar macular hole formation in chronic cystoid macular edema associated with retinal vein occlusion. Jpn J Ophthalmol 55(5):506–513